Therapeutic use of the retinoblastoma susceptibility gene product
US5851991A · kind A · utility
13Cited by
7References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 13, 1994 |
| Grant date | Dec 22, 1998 |
| Priority date | — |
| Expiry date | Sep 13, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.